Edition:
United Kingdom

NanoCarrier Co Ltd (4571.T)

4571.T on Tokyo Stock Exchange

669JPY
15 Dec 2017
Change (% chg)

¥-8 (-1.18%)
Prev Close
¥677
Open
¥668
Day's High
¥684
Day's Low
¥667
Volume
287,600
Avg. Vol
271,666
52-wk High
¥992
52-wk Low
¥618

Latest Key Developments (Source: Significant Developments)

NanoCarrier signs license preferential negotiating rights agreement with AccuRna
Monday, 4 Dec 2017 

Dec 4 (Reuters) - NanoCarrier Co Ltd <4571.T> ::Says it and AccuRna Inc entered into a preferential negotiating rights agreement on exclusive right to license of drug development based on co's gene delivery technology.Co will get payment from AccuRna according to the agreement.Co also plans to inject capital into AccuRna Inc .  Full Article

VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Nanocarrier Co Ltd <4571.T>:VBL Therapeutics and Nanocarrier Co Ltd sign exclusive agreement for VB-111 in Japan.Vascular Biogenics Ltd - ‍Nanocarrier receives exclusive rights to VB-111 in Japan, VBLT retains rights in rest of world​.Vascular - Pursuant to agreement, VBLT to supply nanocarrier with VB-111.Vascular - Nanocarrier will be responsible for all regulatory, other clinical activities necessary for commercialization of VB-111 in Japan.Vascular - VBLT receives up-front payment of $15 million & is entitled to receive greater than $100 million in development & commercial milestone payments​.Vascular Biogenics Ltd - ‍VBLT will also receive tiered royalties on net sales in high-teens​.Vascular Biogenics Ltd - ‍Other terms of agreement not disclosed​.  Full Article

Nanocarrier signs exclusive agreement with VBL Therapeutics for VB-111 in Japan
Monday, 6 Nov 2017 

Nov 6 (Reuters) - NanoCarrier Co Ltd <4571.T>:Says co signs an exclusive license agreement with VBL Therapeutics, for the development, commercialization, and supply of ofranergene obadenovec ("VB-111") in Japan.Under terms of the agreement, VBL Therapeutics will supply the co with VB-111, and the co will be responsible for all regulatory and other clinical activities necessary for commercialization in Japan.Says VBL Therapeutics will receive up-front payment of $15 million, development and commercial milestone payments and tiered royalties on net sales from the co.  Full Article

NanoCarrier and JCR conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:* Says it and NanoCarrier Co., Ltd <4571.T> conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines .* Under this agreement, Nanocarrier and JCR will integrate the unique technologies and knowledge of both companies, and aim to develop an innovative drug effectively delivered to the brain .  Full Article

NanoCarrier says patent for nucleic acid delivery technology granted by European Patent Office
Monday, 1 Aug 2016 

NanoCarrier Co Ltd <4571.T>:Says patent related to nucleic acid delivery technology granted by the European Patent Office regarding particle composition and pharmaceutical composition.  Full Article

NanoCarrier says clinical trial of NC-6004
Wednesday, 22 Jun 2016 

NanoCarrier Co Ltd <4571.T>:Says it submitted CTA (Clinical Trial Authorization) of NC-6004 to regulatory authorities of EU regional.  Full Article

NanoCarrier receives patent recognition in U.S
Monday, 4 Apr 2016 

NanoCarrier Co Ltd:Received patent recognition from United States Patent and Trademark Office, for particle composition as well as its pharmaceutical composition.  Full Article

NanoCarrier enters new development agreement with ALBION
Thursday, 24 Mar 2016 

NanoCarrier Co Ltd:Enters a new development agreement with ALBION co.,ltd., to cooperate on joint development of products in skin related area.  Full Article

NanoCarrier signs license agreement with Tokyo-based company
Wednesday, 16 Mar 2016 

NanoCarrier Co Ltd:Says signed exclusive license contract with sub-licenses right with a Tokyo-based company regarding the company's gene delivery technology.Says the Tokyo-based company engaged in research and development of pharmaceuticals by using drug delivery system.  Full Article

NanoCarrier announces patent assessment in U.S for substance patent on gene carrier
Wednesday, 13 Jan 2016 

NanoCarrier Co Ltd:Announced patent assessment for patent application of substance patent on gene carrier by United States Patent and Trademark Office.  Full Article

BRIEF-NanoCarrier signs license preferential negotiating rights agreement with AccuRna

* Says it and AccuRna Inc entered into a preferential negotiating rights agreement on exclusive right to license of drug development based on co's gene delivery technology